Cue

Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
수요일, 2월 28, 2024
Biotechnology, Health Technology, Health, Telemedicine, Virtual Medicine, Telephone, Cue

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024.

Key Points: 
  • Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024.
  • In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Events section of the Company’s website at investors.cuehealth.com .
  • A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

S32 Names Dr. Andy Conrad as General Partner

Retrieved on: 
목요일, 2월 22, 2024
Cloud, GV (company), Google Cloud, DeepMind, PALO, Doctor of Philosophy, GV, AI, Cue, General partnership, Investment, Data science, X Development, Coinbase, University, Google AI, Labcorp, Business, Corporate development, Creativity, Verily, Cryptocurrency

PALO ALTO, Calif., Feb. 22, 2024 /PRNewswire/ -- S32, a leading venture capital firm founded by Bill Maris after building Google Ventures, today proudly announced the appointment of Dr. Andy Conrad, a leader in the application of technology and advanced data science, as General Partner.

Key Points: 
  • PALO ALTO, Calif., Feb. 22, 2024 /PRNewswire/ -- S32, a leading venture capital firm founded by Bill Maris after building Google Ventures, today proudly announced the appointment of Dr. Andy Conrad, a leader in the application of technology and advanced data science, as General Partner.
  • Dr. Conrad previously held numerous senior roles at Google, having most recently founded and served as the CEO and Executive Chairman of Verily Life Sciences (previously "Google Life Sciences").
  • Before joining Google, Dr. Conrad was the Chief Scientific Officer of Laboratory Corporation of America ("LabCorp"), one of the largest clinical laboratory companies in the world.
  • "Andy is precisely who we want on our side working on behalf of our entrepreneurs and investors," said Andy Harrison, CEO and General Partner of S32.

Equal Opportunity Schools Recognized as Innovator by Microsoft, Stanford and Bill and Melinda Gates Foundation

Retrieved on: 
목요일, 2월 8, 2024
Momentum, EOS, Education, GPA, HAI, Achievement Medal, Microsoft, Psychological safety, Condition, NTA, Chicago Public Schools, Student, Corporation, Partnership, Conference, AI, Digital Promise, National Conference, AASA, Black, Cue, Digital, Stanford University, African Americans, City, Artificiality, Bill, Human-centered computing, Learning, Hasso Plattner Institute, Management

SEATTLE, Feb. 8, 2024 /PRNewswire/ -- Equal Opportunity Schools (EOS), the nationwide nonprofit leader in partnering with US high schools to provide student insights and accelerate college and career access demonstrates the power of collaboration with industry leaders including Microsoft, Stanford and the Bill and Melinda Gates Foundation.

Key Points: 
  • At Microsoft's inaugural Global Nonprofit Leaders Summit, EOS was highlighted for its data-driven, student-centered partnerships with high schools around the country.
  • Yesterday, Equal Opportunity Schools presented at the AccelerateEd convening hosted by the Education Strategy Group and the Bill & Melinda Gates Foundation.
  • Recently, Equal Opportunity Schools released a special report on Psychological Safety by Dr. Erin Bogan, Sr. Director of Research & Impact.
  • Thanks to philanthropic support, Equal Opportunity Schools is offering 100 US School Districts matching grant opportunities to partner with EOS for the 2024-2025 School Year.

Cue Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
수요일, 11월 8, 2023
Health, Medical Devices, Telemedicine, Virtual Medicine, FDA, RSV, Herpes simplex, EBITDA, GAAP, PCR, De novo, COVID, COVID-19, Cue, EUA, Cassette tape, Pharmaceutical industry, Payment card, Video game, Bookkeeping, Microbiology Spectrum

Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023.

Key Points: 
  • Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023.
  • I’m proud of the Cue team for the strong execution across all fronts.”
    Revenue was $17.5 million for the third quarter of 2023.
  • GAAP net loss in the third quarter of 2023 was $47.0 million and earnings per diluted share was a loss of $0.31, an improvement of $0.24 from the second quarter of 2023.
  • Cue ended the third quarter with cash of $111.5 million and the company continues to operate with no debt obligations.

Cue Health to Announce Third Quarter 2023 Financial Results

Retrieved on: 
수요일, 10월 25, 2023
Health, Telemedicine, Virtual Medicine, Health Technology, Other Health, Managed Care, General Health, Telephone, Cue

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023.

Key Points: 
  • Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023.
  • In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Events section of the Company’s website at investors.cuehealth.com.
  • A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

Concerned Stockholders of Cue Health Send Letter to Board

Retrieved on: 
토요일, 10월 7, 2023
Health, General Health, FDA, COVID-19, Concerned, Optimism, Cue, Weather, Stock dilution, Letter, Pharmaceutical industry, Nursing

As you know, I was the founder of Cue Health, Inc. (“Cue Health” or the “Company”) and an investor from the Company’s first seed round, through subsequent rounds of its financing, and together with certain other stockholders of the Company (the “Concerned Stockholders”), own approximately 7.5% of Cue Health’s outstanding stock.

Key Points: 
  • As you know, I was the founder of Cue Health, Inc. (“Cue Health” or the “Company”) and an investor from the Company’s first seed round, through subsequent rounds of its financing, and together with certain other stockholders of the Company (the “Concerned Stockholders”), own approximately 7.5% of Cue Health’s outstanding stock.
  • Since its founding in 2010, Cue Health has developed game-changing diagnostics to enable lab-quality care at home, work or at the point of care.
  • The Concerned Stockholders believe that the Board must take immediate action to stabilize the Company, substantially reduce its cash burn, and focus on its core diagnostic business.
  • The Concerned Stockholders urge the Board to heed our voices as long-term stockholders and take action today.

Peer-Reviewed Independent Study Published in Microbiology Spectrum Finds Cue Health’s Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

Retrieved on: 
수요일, 10월 4, 2023
Biotechnology, Health, COVID-19, Clinical Trials, Infection, Microbiology, De novo, RNS, Landing slot, ISO, American Society for Microbiology, RT-PCR, FH, COVID-19 testing, Trial of the century, Viral load, Immunodeficiency, FDA, RT, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Cue, PCR, Food, Pharmaceutical industry, Nursing, Vaccine, Microbiology Spectrum

The study, published in Microbiology Spectrum, a journal produced by the American Society for Microbiology, presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.

Key Points: 
  • The study, published in Microbiology Spectrum, a journal produced by the American Society for Microbiology, presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.
  • The findings from paired testing revealed a 99.4% match between results from Cue’s test and the reference PCR tests with 100% clinical sensitivity to detect positive cases, yielding no false negatives.
  • To further expand its diagnostic test menu for at-home and point-of-care use, Cue has made a number of other submissions with the FDA.
  • Cue did not provide funding or any other support of the study.

Cue Health Adopts Limited-Duration Shareholder Rights Plan

Retrieved on: 
목요일, 9월 21, 2023
Health Technology, Health, Medical Supplies, Telemedicine, Virtual Medicine, Cyprus Securities and Exchange Commission, Shareholder rights plan, Growth, Security (finance), Cue

Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration shareholder rights plan (the “Rights Plan”) to protect the long-term interests of all shareholders.

Key Points: 
  • Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration shareholder rights plan (the “Rights Plan”) to protect the long-term interests of all shareholders.
  • The Board adopted the Rights Plan in response to a rapid accumulation of shares by a third party.
  • The Rights Plan is effective immediately and has a one-year term, expiring on September 20, 2024.
  • The Rights Plan does not preclude the Board from considering an offer that recognizes the full value of Cue.

Tarsadia Investments Sends Letter to Board of Cue Health, Inc.

Retrieved on: 
목요일, 8월 31, 2023
General Health, Professional Services, Health, Finance, Advisory board, Exercise, IPO, Failure, Uka Tarsadia University, Marketing, COVID-19, Research, COVID, EBITDA, Risk, Growth, Letter, Nursing, Pharmaceutical industry, Management, Pharmacy, Cue

Tarsadia has previously expressed our concerns through multiple meetings with management, a letter sent to the Board on August 3, 2023, and during a meeting we conducted with members of the Board on August 22, 2023.

Key Points: 
  • Tarsadia has previously expressed our concerns through multiple meetings with management, a letter sent to the Board on August 3, 2023, and during a meeting we conducted with members of the Board on August 22, 2023.
  • Cue should focus on supporting its diagnostic products and curtail its non-core businesses: Cue Lab and Cue Pharmacy.
  • Cue must appoint independent stockholder representatives to the Board who can contribute a sense of urgency and fresh perspective to Board deliberations.
  • The issues facing Cue are critical and urgent, and we are available to discuss next steps at your earliest convenience.

Cue Health Reports Second Quarter 2023 Financial Results

Retrieved on: 
수요일, 8월 9, 2023
Medical Devices, FDA, Health, Health Technology, Health Insurance, COVID-19, EUA, Biomedical Advanced Research and Development Authority, Optimism, Pharmacy, De novo, GAAP, COVID, EBITDA, RSV, Influenza, Growth, BARDA, Cue, Video game, Pharmaceutical industry, Security (finance)

Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the second quarter 2023.

Key Points: 
  • Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the second quarter 2023.
  • Submitted the Cue RSV Molecular Test as a De Novo submission to the FDA for at-home and point-of-care use during the second quarter.
  • These milestones, together with the early positive signs we’re seeing from Cue Lab and Cue Pharmacy, gives us optimism and confidence in the future of the Cue Health platform.”
    Revenue was $9.9 million for the second quarter of 2023.
  • GAAP net loss in second quarter of 2023 was $83.9 million and earnings per diluted share was a loss of $0.55 or an improvement of $0.12 from the second quarter of 2022.